Global Alzheimer’s Platform (GAP) Foundation Unites 58 of the World’s Leading Research Sites With Goal of Doubling Clinical Trial Participation in USA

More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked Sites
Kansas City Pilot Program Increased Volunteer Trial Participation by 292%

WASHINGTON, D.C. – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone.  It is projected that 14 million people in the U.S. will be afflicted with Alzheimer’s disease by 2050. The Global Alzheimer’s Platform (GAP) Foundation is implementing a new model designed to accelerate clinical trials and increase participation in research.  Results of GAP’s Kansas City initiative, the Memory Strings Kansas City Alliance, demonstrated a 292% growth in people contacting their local Alzheimer’s disease research center.  The Kansas City Alliance initiative also cut trial enrollment time in half. GAP’s initiatives are targeted to reduce the clinical trial cycle times by up to two years, with the goal of speeding the delivery of lifesaving therapies to patients.

Read the full release here.